**Supplementary Table 1**. **Odds ratios of the positive predictive values afforded by iFOBT for all neoplasia, invasive and non-invasive cancer, and colorectal adenoma in patients using DOAC, warfarin, aspirin, and thienopyridine compared to non-users ( N = 5,173).**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Outcomes** |  |  |  |
|  | **All neoplasia**  **(N = 2399 )** | **Non-neoplasia**  **(N = 2774)** | **Adjusted odds ratio**  **(95% confidence interval)** | **P-value** |
| DOAC non-users | 2,275 (94.83) | 2,680 (96.61) | 1 |  |
| DOAC users | 124 (5.17) | 94 (3.39) | 1.42 (1.03–1.94) | **0.030** |
| Warfarin non-users | 2,321 (96.75) | 2,683 (96.72) | 1 |  |
| Warfarin users | 78 (3.25) | 91 (3.28) | 1.25 (0.87–1.79) | 0.225 |
| Aspirin non-users | 2,177 (90.75) | 2,547 (91.82) | 1 |  |
| Aspirin users | 222 (9.25) | 227 (8.18) | 0.95 (0.77–1.19) | 0.679 |
| Thienopyridine non-users | 2,351 (98.00) | 2,725 (98.23) | 1 |  |
| Thienopyridine users | 48 (2.00) | 49 (1.77) | 0.94 (0.60–1.45) | 0.765 |
|  | **Invasive cancer**  **(N = 141)** | **Non-cancer**  **(N = 5,032)** |  |  |
| DOAC non-users | 132 (93.62) | 4,823 (95.85) | 1 |  |
| DOAC users | 9 (6.38) | 209 (4.15) | 1.43 (0.68–2.98) | 0.338 |
| Warfarin non-users | 134 (95.04) | 4,870 (96.78) | 1 |  |
| Warfarin users | 7 (4.96) | 162 (3.22) | 1.53 (0.65–3.58) | 0.331 |
| Aspirin non-users | 126 (89.36) | 4,598 (91.38) | 1 |  |
| Aspirin users | 15 (10.64) | 434 (8.62) | 0.87 (0.48–1.59) | 0.650 |
| Thienopyridine non-users | 139 (98.58) | 4,937 (98.11) | 1 |  |
| Thienopyridine users | 2 (1.42) | 95 (1.89) | 0.53 (0.12–2.26) | 0.392 |
|  | **Non-invasive cancer**  **(N = 582)** | **Non-cancer**  **(N = 4,591)** |  |  |
| DOAC non-users | 542 (93.13) | 4,413 (96.12) | 1 |  |
| DOAC users | 40 (6.87) | 178 (3.88) | 1.27 (0.75–2.17) | 0.378 |
| Warfarin non-users | 557 (95.70) | 144 (3.14) | 1 |  |
| Warfarin users | 25 (4.30) | 4,447 (96.86) | 1.87 (1.02–3.43) | **0.043** |
| Aspirin non-users | 517 (88.83) | 4,207 (91.64) | 1 |  |
| Aspirin users | 65 (11.17) | 384 (8.36) | 1.01 (0.66–1.53) | 0.973 |
| Thienopyridine non-users | 14 (97.59) | 4508 (98.19) | 1 |  |
| Thienopyridine users | 568 (2.41) | 83 (1.81) | 1.53(0.70–3.36) | 0.286 |
|  | **Adenoma**  **(N = 2,290)** | **Non-adenoma**  **(N = 2,883)** |  |  |
| DOAC non-users | 2,174 (94.93) | 2,781 (96.46) | 1 |  |
| DOAC users | 116 (5.07) | 102 (3.54) | 1.32 (0.97–1.80) | 0.083 |
| Warfarin non-users | 2,218 (96.86) | 2,786 (96.64) | 1 |  |
| Warfarin users | 72 (3.14) | 97 (3.36) | 1.18 (0.82–1.68) | 0.370 |
| Aspirin non-users | 2,081 (90.87) | 240 (8.32) | 1 |  |
| Aspirin users | 209 (9.13) | 2,643 (91.68) | 0.95 (0.76–1.19) | 0.647 |
| Thienopyridine non-users | 2,243 (97.95) | 2,833 (98.27) | 1 |  |
| Thienopyridine users | 47 (2.05) | 50 (1.73) | 1.06 (0.68–1.65) | 0.790 |

Adjusted odds ratios were calculated using factors of patient demographic factors, including age, sex, physical status, family cancer history, family colorectal cancer history, smoking status, alcohol consumption, drug use, colonoscopy history, preparation quality, incomplete coecal intubation, insertion time (calculated using imputed data), and hospital.